Literature DB >> 8595810

Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG).

J W Rohen1, E Lütjen-Drecoll, C Flügel, M Meyer, I Grierson.   

Abstract

Thirty-one trabeculectomy specimens of patients suffering from primary open-angle glaucoma (POAG) who had received no, or only minor, medication prior to surgery were ultrastructurally and quantitatively analysed. Most of the specimens revealed thickened trabeculae, increased amounts of plaque-material deposited within the cribriform layer and an abundance of long spacing (lattice) collagen. The uveal meshwork was partly deprived of cells whereas the cribriform layer often contained numerous enlarged, light cells with many small mitochondria and lysosomes but no prominent endoplasmic reticulum or Golgi complexes. The quantitation of sheath-deprived plaque material (SD plaques) in a defined area of inner and outer wall of Schlemm's canal showed no significant difference between the untreated cases studied here and the treated ones studied previously. However, both groups had significantly higher amounts of SD plaque material in the inner wall than normal controls of a similar age range.

Entities:  

Mesh:

Year:  1993        PMID: 8595810     DOI: 10.1006/exer.1993.1085

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  77 in total

1.  Glycans of the trabecular meshwork in primary open angle glaucoma.

Authors:  S A Chapman; R E Bonshek; R W Stoddart; E O'Donoghue; K Goodall; D McLeod
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

2.  Thermally labile components of aqueous humor potently induce osteogenic potential in adipose-derived mesenchymal stem cells.

Authors:  Joshua T Morgan; Heung Sun Kwon; Joshua A Wood; Dori L Borjesson; Stanislav I Tomarev; Christopher J Murphy; Paul Russell
Journal:  Exp Eye Res       Date:  2015-02-24       Impact factor: 3.467

3.  Aggregated myocilin induces russell bodies and causes apoptosis: implications for the pathogenesis of myocilin-caused primary open-angle glaucoma.

Authors:  Gary Hin-Fai Yam; Katarina Gaplovska-Kysela; Christian Zuber; Jürgen Roth
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  Extracellular matrix in the trabecular meshwork.

Authors:  Ted S Acott; Mary J Kelley
Journal:  Exp Eye Res       Date:  2008-01-25       Impact factor: 3.467

5.  The Role of Wnt/β-Catenin Signaling and K-Cadherin in the Regulation of Intraocular Pressure.

Authors:  Hannah C Webber; Jaclyn Y Bermudez; J Cameron Millar; Weiming Mao; Abbot F Clark
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-03-01       Impact factor: 4.799

6.  Transforming growth factor-beta2 utilizes the canonical Smad-signaling pathway to regulate tissue transglutaminase expression in human trabecular meshwork cells.

Authors:  Tara Tovar-Vidales; Abbot F Clark; Robert J Wordinger
Journal:  Exp Eye Res       Date:  2011-06-24       Impact factor: 3.467

Review 7.  The microfibril hypothesis of glaucoma: implications for treatment of elevated intraocular pressure.

Authors:  John Kuchtey; Rachel W Kuchtey
Journal:  J Ocul Pharmacol Ther       Date:  2014-02-12       Impact factor: 2.671

8.  Secreted protein acidic and rich in cysteine (SPARC)-null mice exhibit more uniform outflow.

Authors:  Swarup S Swaminathan; Dong-Jin Oh; Min Hyung Kang; Ruiyi Ren; Rui Jin; Haiyan Gong; Douglas J Rhee
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-21       Impact factor: 4.799

9.  Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2.

Authors:  Marcus Kernt; Aljoscha S Neubauer; Kirsten H Eibl; Armin Wolf; Michael W Ulbig; Anselm Kampik; Cristoph Hirneiss
Journal:  Clin Ophthalmol       Date:  2010-07-21

10.  RNA interference as a gene silencing therapy for mutant MYOC protein in primary open angle glaucoma.

Authors:  Mao Li; Jianjiang Xu; Xueli Chen; Xinghuai Sun
Journal:  Diagn Pathol       Date:  2009-12-16       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.